Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 22, 2024Cancer Research

Abstract 4068: In vitro masked effect, in vivo anti-tumor activity and toxicology study of KGX101, an interleukin-12 prodrug, in monotherapy or in combination with anti-PD-L1 antibody

View Full Paper
Ask AI
Bookmark
Share

Authors

SYShumin YangShanghai Advanced Research InstituteNLNuo LiQingdao UniversityJWJing WangFujian University of Traditional Chinese Medicine

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Yang et al. (2024) studied this question.

synapsesocial.com/papers/68e72cd9b6db6435876a6548https://doi.org/10.1158/1538-7445.am2024-4068
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract CT291: First-in-human study of the IL-12 Prodrug KGX101 demonstrates tumor-microenvironment specific activation, promising antitumor activity, and a manageable safety profile in advanced or metastatic melanoma2026
  2. 2Abstract 4320: Rational design of a repeated-dosing schedule for KNP-101 guided by IFN-γ regulation2026
  3. 3Abstract 3798: In vivo results of AGX101, a TM4SF1-directed tubulin inhibitor conjugate, in combination with immune checkpoint inhibitors2026
  4. 4Abstract 4331: ZL-1222, a PD-1-targeted potency-reduced IL-12 immunocytokine, overcomes PD-1 resistance and enhances antitumor immunity with an accepted safety profile2026
  5. 5Data from XTX301, a Tumor-Activated Interleukin-12 Has the Potential to Widen the Therapeutic Index of IL12 Treatment for Solid Tumors as Evidenced by Preclinical Studies2024